The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs)

Abduelmenem Alashkham (Lead / Corresponding author), Catherine Paterson, Phyllis Windsor, Allan Struthers, Petra Rauchhaus, Ghulam Nabi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Micro-Abstract Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are anti-hypertensive medication and have been linked to prostate cancer, but their effect on biochemical recurrence (BR) remains unexplored. The aims of the study were to evaluate the incidence and risk of BR in men receiving ACEIs/ARBs after radical radiotherapy with adjuvant∖neoadjuvant hormone treatment. The administration of ACEIs/ARBs were associated with a reduced risk of BR.

Original languageEnglish
Pages (from-to)398-405
Number of pages8
JournalClinical Genitourinary Cancer
Volume14
Issue number5
Early online date12 Mar 2016
DOIs
Publication statusPublished - Oct 2016

Keywords

  • Biochemical recurrence
  • Hormonal therapy
  • Prostate cancer
  • Radiotherapy
  • Renin angiotensin system

Fingerprint Dive into the research topics of 'The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs)'. Together they form a unique fingerprint.

  • Equipment

  • Cite this